

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Bendamustine in combination with rituximab for the first-line treatment of indolent non-Hodgkin's lymphoma

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Napp Pharmaceuticals (bendamustine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Cancer 52 • Cancer Black Care • Cancer Equality • Counsel and Care • Equalities National Council • Helen Rollason Heal Cancer Charity • Leukaemia CARE • Leukaemia Society (UK) • Lymphoma Association • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association for Services to the Elderly • British Blood Transfusion Society • British Committee for Standardisation in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Haematology • British Society of Blood and Bone Marrow Transplantation • Cancer Networks Pharmacists Forum 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Accord (doxorubicin) • Actavis (doxorubicin, prednisolone) • Alliance Pharmaceuticals (prednisolone) • Almus Pharmaceuticals (prednisolone) • Baxter Healthcare (cyclophosphamide) • Co-Pharma (prednisolone) • Genus Pharmaceuticals (vincristine) • Hospira (doxorubicin, vincristine) • LPC Medical (prednisolone) • Medac (doxorubicin) • Metwest Pharmaceuticals (prednisolone) • Pfizer (cyclophosphamide, doxorubicin) • Roche Products (rituximab) • Teva UK (doxorubicin, prednisolone, vincristine) • Winthrop Pharmaceuticals (prednisolone) • Wockhardt (prednisolone)

National Institute for Health and Clinical Excellence
 Matrix for bendamustine in combination with rituximab for the first-line treatment of indolent non Hodgkin's lymphoma

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Cancer Research UK • National Blood Service • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiology • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Black Country PCT Cluster • Department of Health • North of Tyne PCT Cluster • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Elimination of Leukaemia Fund • Institute of Cancer Research • Leukaemia & Lymphoma Research • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute of the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Kleijnen Systematic Reviews • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.